Compare TMCWW & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMCWW | BCTXZ |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Canada | Canada |
| Employees | 47 | 4 |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | TMCWW | BCTXZ |
|---|---|---|
| Price | $1.05 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.8K | 13.2K |
| Earning Date | 03-24-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.12 |
| 52 Week High | $3.84 | $1.20 |
| Indicator | TMCWW | BCTXZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 46.22 |
| Support Level | $0.82 | $0.14 |
| Resistance Level | $1.08 | $0.21 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 40.29 | 46.56 |
TMC The Metals Co Inc is a deep-sea minerals exploration company focused on the collection, processing, and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ). Polymetallic nodules are discrete rocks that sit unattached to the seafloor, occur in notable quantities in the CCZ, and have high concentrations of nickel, copper, cobalt, and manganese in a single rock. The company believes these four metals contained in the polymetallic nodules are critical for energy infrastructure and industrial manufacturing. The Company's business consists of only one operating segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.